# **QUALITY OF LIFE AND COVID-19** PHOBIA OF CANCER PATIENTS RECEIVING CHEMOTHERAPY IN A STATE HOSPITAL **DURING PANDEMIC:** A CROSS SECTIONAL STUDY

S. HIDIROĞLU<sup>1</sup>, B.N. ATAOĞLU<sup>1</sup>, E. PASTIRMACIOĞLU<sup>2</sup>, G. ÇAKIR<sup>2</sup>, S. YORGANCI<sup>2</sup>, A. GHACHEM<sup>2</sup>

<sup>1</sup>Department of Public Health, Marmara University, Faculty of Medicine, Istanbul, Turkey <sup>2</sup>Marmara University, Faculty of Medicine, Istanbul, Turkey

Abstract - Objective: COVID-19 pandemic has become a global public health problem and led to phobia among people. There is also no doubt that the COVID-19 pandemic had a great impact on the quality of people's lives. The goal of this study was to assess the factors that might be affecting the quality of life and COVID-19 phobia of the cancer patients receiving chemotherapy.

Materials and Methods: This cross-sectional study was conducted between November 2021 and April 2022 in an outpatient chemotherapy unit within a state hospital in Istanbul. Participants' data was gathered by a questionnaire that had 3 components: participants' characteristics, the COVID-19 phobia scale, and the WHOQOL-BREF scale.

Results: The results showed that perceived economic status, education level, having comorbidities, having a caregiver and who is the caregiver had an impact on the Quality of Life, and people who have an acquaintance who died due to COVID-19 had higher COVID-19 phobia total score. Furthermore, it was seen that as the age or COVID-19 phobia total score increased, each component of the Quality of Life score decreased.

Conclusions: Quality of life and COVID-19 phobia of cancer patients were observed to be inversely proportional in chemotherapy receiving patients in a state hospital in Istanbul.

KEYWORDS: Cancer, Quality of life, COVID-19, Phobia.

#### INTRODUCTION

Since its declaration as a pandemic by the World Health Organization on 11th March 2020, SARS-CoV-2 and the resulting illness COVID-19, had become a worldwide public health problem<sup>1,2</sup>. In addition to being a worldwide public health problem, COVID-19 resulted in emotional distress, anxiety, depression, and other psychiatric problems<sup>2,3</sup>. Like similar pandemics that happened in the past such as H1N1, Ebola, and MERS,

COVID-19 triggered the feeling of helplessness, fear, anxiety, and phobia<sup>3-6</sup>.

Phobia is defined as an "overwhelming and debilitating fear of an object, place, situation, feeling or animal"7. Coronaphobia is a specific and excessive fear of getting infected by COVID-19. People with coronaphobia are always on alert. The idea of losing someone they care makes them sad and stressed8.

The World Health Organization defines quality of life as an "individual's perception of their posi-



1 This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

DOI: 10.32113/wcrj\_20229\_2390

# World Cancer Research Journal

tion in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns". Quality of life is a complex concept affected by various factors including social environment, expectations from life, beliefs, psychological and physical status and there is no doubt that the COVID-19 pandemic had an impact on people's life quality.

During the pandemic, cancer patients constituted a significantly vulnerable population with their weakened immune system setting the ground for infections and poor course of illnesses<sup>3</sup>. Nowadays, with improvements in technology, there are different strategies for cancer treatment. One of the most common strategies is chemotherapy; although most cancer patients receiving chemotherapy continue to their daily-life routine without any restrictions, tiredness and possible side effects after chemotherapy have a dramatic impact on their quality of life<sup>10</sup>. The conducted studies in recent years showed that patients' quality of life, especially the ones suffering from a chronic illness, for instance, as cancer, is as important as their survival rates from the disease. Assessing the quality of life helps clinicians to see the potential benefits and risky aspects of the treatment they provide and thus they can arrange the appropriate treatment programs for better outcomes<sup>11</sup>.

The goal of this study was to define the factors that might be affecting the COVID-19 phobia and quality of life of cancer patients receiving chemotherapy who are a high-risk group during the pandemic and vulnerable to infections.

## **MATERIALS AND METHODS**

#### Design, setting, and sample

This present study is a cross-sectional study that took place between September 2021 and April 2022. Participants of this study were cancer patients receiving chemotherapy at an outpatient chemotherapy unit within a state hospital in İstanbul. The study sample consisting of 242 patients was calculated using the OpenEpi program. Participant inclusion criteria were as followed: a) being 18 years or older; b) having no apparent cognitive impairment; c) being able to read and understand Turkish.

#### **INSTRUMENTS**

Information was gathered from participants by using a questionnaire. The questionnaire consisted of 3 parts: participants' characteristics, COVID-19 phobia, and quality of life scales, respectively.

The first part was designed by the researchers and included questions to evaluate participants' age, gender, marital status, level of education, economic status, and cancer type. To assess COVID-19 diagnosis, patients were asked if they or any of their friends/relatives previously had a positive COVID-19 PCR test result and if they needed to stay in hospital because of the infection. Furthermore, patients' vaccination status was questioned and participants who had at least two shots were accepted as vaccinated for COVID-19.

The second part included the COVID-19 phobia scale, a valid and reliable scale developed by Arpaci et al<sup>12</sup>. The scale has 20 questions and psychological, somatic, social, and economic sub-scales. All of the questions have likert scale response options where 1 strongly disagree to 5 strongly agree. The sum of all subscale scores gives the total score which can range from 20 to 100 points. Higher scores show higher COVID-19 phobia.

Third and the final part of the questionnaire includes the World Health Organization Quality of Life scale's abbreviated form (WHO-QOL-BREF)<sup>13</sup>. It is a reliable and valid scale that has 26 questions and four subdomains which are physical health, mental health, social health, and environmental well-being. All questions were answered according to the likert scale. Higher scores in each subdomain indicate better quality of life.

#### **ETHICAL CONSIDERATIONS**

All procedures were in accordance with the Ethical Standards and with the Declaration of Helsinki. This study was also approved by the Local Ethics Committee (Protocol Number: 08.10.2021.1102).

#### **PROCEDURE**

Data was gathered between November 2021 and April 2022 in the chemotherapy unit on week-days from 09:00 to 16:00. First, the patients who met the inclusion criteria were informed about the study and were asked if they wanted to participate. Patients who are volunteers signed the informed consent form. Questionnaires were filled out by the researchers as they were interviewing the patients. Each questionnaire took 8-12 minutes to complete.

## **STATISTICAL ANALYSIS**

After data gathering was completed, the analysis of collected data started in April 2022. IBM SPSS (Armonk, NY, USA) was used for analysis and

Microsoft Excel was used for making tables. As the data wasn't normally distributed, Mann Whitney U and Kruskal Wallis tests were conducted for comparative analyses. Spearman Correlations were done between continuous data and scores. Differences were considered statistically significant at p < 0.05.

#### **RESULTS**

A total of 242 patients had been reached (Table 1). Half of the participants were female. The mean age of the participants was  $57.9 \pm 11.9$  years. Most of the participants had a caregiver; 59.4% of them stated their partner (spouse, lover) as the caregiver, whereas 30.8% stated their children as the caregivers, and the rest of the answers classified as "other" (9.8%). The most common types of cancer among the population were colorectal (21.9%), breast (21.5%), and hematological cancers (11.2%) in origin. More than half of the participants had comorbidities and the most common diseases were hypertension (28.9%), diabetes (16.1%), and cardiovascular system diseases (7.4%).

The COVID-19 phobia scale total score median point was 45.50 (interquartile range (IQR): 12.00); the psychological sub-scale was 15 (IQR: 7.00), the somatic sub-scale point was 10.00 (IQR: 2.00), the social sub-scale 13 (IQR: 7.00), and the economic sub-scale point was 8.00 (IQR: 2.25). Based on the answers given to the quality-of-life scale, the physical health sub-scale median point was 12.00 (IQR: 3.43), the psychological sub-scale median point was 13.33 (IQR: 3.33), the social relations sub-scale median point was 14.67 (IQR: 2.67), and the environmental health sub-scale median point was 14.50 (IQR: 2.00).

The relationship between the characteristics of the participants and the COVID-19 phobia and quality of life scores is shown in Table 2 and Table 3. The variables of gender, marital, and employment status were not associated with the COVID-19 phobia or quality of life. There was a statistically significant but weak inverse relationship between age and all subscales of quality of life. As the age increased, quality of life subscale scores decreased. When the perceived economical state and quality of life sub-scales were compared, a statistically significant difference was observed in all quality-of-life sub-scales. The economic state increasing from poor to good

indicates that quality of life increases as economical state is getting better (p < 0.001, p = 0.006, p=0.016, p<0.001, respectively). Moreover, after comparing the educational status and quality of life sub-scales, it has been seen that there was a significant difference in the environmental health sub-scale (p=0.030). When the participants who have or don't have a disease other than cancer were compared with COVID-19 phobia subscales, statistical significance was observed only in somatic and economical sub-scales (p=0.029, p=0.009, respectively). When the same variable was compared with the quality of life sub-scales, it was seen that participants who have comorbidities got lower scores in the physical health and psychological health sub-scales of quality of life (p=0.027, p=0.020). There was no statistically significant difference between perceived economical state and COVID-19 phobia (p>0.05).

Participants who know someone who died because of COVID-19 got a borderline significantly higher total score on the COVID-19 phobia scale than the ones who don't know someone who died because of COVID-19 (p=0.049). When the variable was compared with the COVID-19 phobia sub-scale and quality of life sub-scale, it was found that the ones who have an acquaintance who died because of COVID-19 got statistically significant higher scores in psychological, somatic, and economical sub-scales of COVID-19 phobia, while they were getting statistically significant lower scores in social health sub-scale of quality of life (p=0.020, p=0.038, p=0.046, p=0.030, respectively). When we compared the situation of participants having a caregiver and quality of life subscales, it was observed that participants who have a caregiver got higher scores on the social relations sub-scale of quality of life (p<0.001). When we compared the variable of who is the caregiver with COVID-19 phobia subscales, it was statistically significant only in the economical sub-scale (p=0.006). When the same variable was compared with the quality-of-life sub-scales, it was found that the participants who state their partner as the caregiver had higher scores in the physical health, psychological and environmental health sub-scales of quality of life (p=0.002, p=0.018, p=0.044, respectively).

Total COVID-19 phobia score and quality of life sub-scales scores were also examined and there was a statistically significant but weak inverse relationship. As the total score of COVID-19 phobia was increasing, all four sub-scales scores of quality of life were decreasing.



# World Cancer Research Journal

**TABLE 1.** Baseline characteristics of participants.

Characteristics		n	%
Gender	Female	121	50.0
	Male	121	50.0
	Total	242	100.0
Marital status	Married	196	81.0
	Single	46	19.0
	Total	242	100.0
Educational status	No education	20	8.3
	Primary education	123	50.8
	Highschool	62	25.6
	Higher education	37	15.3
	Total	242	100.0
Employment status	Currently Working	24	9.9
	Currently Not Working/Retired	218	90.1
	Total	242	100.0
Perceived economic status	Poor	59	24.4
	Moderate	166	68.6
	Good	17	7.0
	Total	242	100.0
Type of cancer	Lung	25	10.3
	Breast	52	21.5
	Stomach	25	10.3
	Hematological origin	27	11.2
	Colorectal	53	21.9
	Gynecological origin	10	4.1
	Bladder	8	3.3
	Thyroid	3	1.3
	Other GIS organs	15	6.2
	Other	24	9.9
	Total	242	100.0
Have a comorbidity	Yes	141	58.3
	No	99	40.9
	Total	240	99.2
Have a caregiver	Yes	223	92.1
	No	17	7.0
	Total	240	99.1
Diagnosed with COVID-19	Yes	84	34.7
	No	158	65.3
	Total	242	100.0
Have an acquaintance died due to COVID-19	Yes	100	41.3
	No	130	53.7
	Total	230	95.0
Had at least two shots COVID-19 vaccine	Yes	218	90.1
	No	23	9.5
	Total	241	99.6

**TABLE 2.** Relationship between characteristics and COVID-19 phobia scale.

*																
Characteristics		of o	The Total Score of COVID-19 Phobia Scale	ore 19 Ie	Psychological sub-scale of COVID-19 Phobia Scale	Psychological scale of COVI Phobia Scale	cal OVID-19 Ile	Som of O	Somatic sub-scale of COVID-19 Phobia Scale	- <i>scale</i> 19 1e	Soci of Pho	Social sub-scale of COVID-19 Phobia Scale	cale 19 ile	Ecor of Pho	conomic sub- of COVID-19 Phobia Scale	Economic sub-scale of COVID-19 Phobia Scale
		Median	IQR*	p-value	Median	IQR	p-value	Median	IQR*	p- <i>valu</i> e	Median	IQR*	p-value	Median	IQR*	p- <i>valu</i> e
Gender	Female	47.00	16.75	0.294	16.00	8.00	0.223	10.00	3.75	0.772	13.00	9.00	0.568	8.00	4.00	0.503
	Male	45.00	12.00		15.00	00.9		10.00	1.00		13.00	00.9		8.00	0.00	
Marital status	Married	45.00	12.75	0.586	15.00	7.00	0.365	10.00	3.00	0.312	13.00	8.00	0.680	8.00	3.75	0.400
	Single	47.00	10.25		15.50	00.9		10.00	0.25		13.00	6.25		8.00	0.00	
Educational status	No education	44.00	19.25	0.479	13.50	7.00	0.295	10.00	4.00	0.170	11.50	9.00	0.560	8.00	3.50	0.112
	Primary education	45.00	12.00		15.00	00.9		10.00	4.00		13.00	8.00		8.00	4.00	
	High school	46.00	11.50		16.00	00.9		10.00	0.25		13.50	7.00		8.00	0.00	
	Higher education	46.00	12.00		15.00	7.50		10.00	4.50		13.00	00.9		8.00	4.00	
Perceived economic status Poor	Poor	45.00	10.00	0.849	15.00	5.00	0.878	10.00	0.00	0.054	12.00	5.00	0.498	8.00	0.00	0.088
	Moderate	46.00	13.25		15.00	7.00		10.00	4.00		14.00	9.00		8.00	4.00	
	Good	47.00	16.50		16.00	8.00		10.00	4.00		13.00	7.00		8.00	4.00	
Employment status	Currently Working	45.00	14.50	0.941	15.00	8.00	0.948	10.00	3.75	096.0	13.00	9.25	0.726	8.00	3.50	0.410
	Currently Not Working/Retired	45.50	12.00		15.00	7.00		10.00	2.00		13.00	7.00		8.00	2.25	
Type of cancer	Lung	41.00	11.00	0.741	14.00	6.50	0.802	10.00	5.00	0.409	13.00	6.50	0.885	8.00	4.00	0.140
	Breast	45.50	21.50		16.00	11.50		10.00	5.00		13.00	9.00		8.00	4.00	
	Stomach	46.00	8.50		15.00	4.50		10.00	2.00		13.00	5.00		8.00	0.00	
	Colorectal	46.00	12.50		15.00	6.50		10.00	0.50		14.00	9.00		8.00	0.00	
	Hematological origin	45.00	16.00		15.00	8.00		10.00	2.00		14.00	9.00		8.00	2.00	
	Gynecological origin	47.50	7.75		15.50	5.50		10.00	2.25		14.00	8.50		8.00	4.00	
	Thyroid	49.00	0.00		17.00	0.00		10.00	0.00		14.00	0.00		8.00	0.00	
	Bladder	50.00	15.50		17.00	8.75		10.00	5.00		13.50	6.25		8.00	0.00	
	Other GIS organs	43.00	00.9		13.00	4.00		10.00	4.00		12.00	4.00		8.00	2.00	
	Other organs	45.00	11.50		16.00	6.75		10.00	0.00		11.50	4.00		8.00	0.00	
Have a comorbidity	Yes	46.00	14.50	0.075	15.00	7.00	0.182	10.00	1.00	0.029	13.00	7.50	0.249	8.00	0.00	0.000
	No	45.00	10.00		15.00	00.9		10.00	5.00		13.00	7.00		8.00	4.00	
Have a caregiver	Yes	46.00	12.00	0.493	15.00	7.00	0.646	10.00	2.00	0.915	13.00	8.00	0.736	8.00	2.00	968.0
	No	45.00	10.50		15.00	5.00		10.00	2.00		13.00	00.9		8.00	4.00	
Who is the caregiver	Partner	45.00	13.50	0.350	15.00	7.00	0.190	10.00	5.00	0.055	13.00	00.6	0.293	8.00	4.00	9000
	Children	46.00	11.50		15.00	00.9		10.00	0.00		12.00	5.00		8.00	0.00	
	Other	47.00	15.25		16.00	00.9		10.00	1.00		13.50	7.00		8.00	0.00	
Diagnosed with COVID-19	Yes	45.00	12.00	0.916	15.00	7.00	0.850	10.00	3.50	0.907	13.00	00.6	0.994	8.00	4.00	0.459
	No	46.00	12.00		15.00	7.00		10.00	1.25		13.00	00.9		8.00	2.00	
Have an acquaintance	Yes	47.00	10.75	0.049	16.00	00.9	0.029	10.00	0.00	0.038	13.00	00.9	860.0	8.00	0.00	0.046
died due to COVID-19	No	45.00	12.25		15.00	7.00		10.00	5.00		13.00	7.00		8.00	4.00	
Had at least two shots	Yes	45.00	12.00	0.511	15.00	7.00	0.756	10.00	2.20	0.142	13.00	7.00	0.485	8.00	2.00	0.627
COVID-19 vaccine	No	47.00	19.00		14.00	11.00		10.00	2.05		14.00	9.00		8.00	4.00	

\*IQR: interquartile range

TABLE 3. Relationship between characteristics and WHOQOL scores.

Conditional participation of the participation of the participation of the participation of the scale of Quality scal														
Female   12.00   2.86   0.648   13.33   3.33   0.576   14.67   2.67   0.111   14.50     Married   12.00   2.86   0.648   13.33   2.67   14.67   2.67   0.111   14.50     Single   12.00   3.44   0.35   13.33   2.67   0.74   14.67   2.67   0.111   14.50     No culturally   12.00   3.44   0.35   13.33   2.67   0.129   2.67   0.077   14.00     Highs reductation   12.00   3.43   0.37   1.467   2.67   0.096   14.00 <th>Characteristics</th> <th></th> <th>Phi sub-s</th> <th>ysical hear cale of Qu f Life scal</th> <th>th iality e</th> <th>Psych sub-s</th> <th>ological h cale of Qu of Life scal</th> <th>ealth Lality e</th> <th>oS s-qns</th> <th>cial relati scale of Q of Life sca</th> <th>ons uality le</th> <th>Envir sub-s</th> <th>onmental scale of Q of Life scal</th> <th>health Lality e</th>	Characteristics		Phi sub-s	ysical hear cale of Qu f Life scal	th iality e	Psych sub-s	ological h cale of Qu of Life scal	ealth Lality e	oS s-qns	cial relati scale of Q of Life sca	ons uality le	Envir sub-s	onmental scale of Q of Life scal	health Lality e
Female   12.00   2.86   0.648   13.33   3.33   0.576   44.67   2.67   0.111   14.50     Marted   12.00   3.34   3.34   13.33   2.67   0.774   44.67   2.67   0.111   14.50     Single   12.00   3.34   0.33   13.33   2.67   0.774   44.67   2.67   0.077   14.60     No celebration   12.00   3.43   0.37   13.33   2.67   0.129   2.67   0.129   1.60   14.60			Median	IQR*	p-value	Median	IQR	p-v <i>alu</i> e	Median	IQR*	p- <i>valu</i> e	Median	IQR*	p-value
Marked   12,57   3,43   13,33   2,67   14,67   2,67   14,50     Singled   12,00   3,14   3,35   13,33   2,67   14,60   267   14,50     Singled   12,00   3,14   3,35   13,33   2,67   14,60   267   14,50     Primary education   12,00   3,43   14,00   2,33   14,67   267   14,00   14,00     High school   12,00   2,29   4,40   3,33   3,47   4,67   267   14,00   14,00     High school   12,00   2,29   4,00   13,33   3,33   4,67   267   14,00   <	Gender	Female	12.00	2.86	0.648	13.33	3.33	0.576	14.67	2.67	0.111	14.50	2.50	0.770
Numrical   12.00   3.29   0.335   13.33   2.67   4.67   2.67   0.067   14.50     No education   10.07   3.29   0.077   12.00   2.00   0.108   13.33   1.33   1.33   1.37   0.07   14.00     Higher education   12.00   3.43   14.00   2.00   0.108   13.33   1.37   1.37   1.50   14.00     Higher education   12.00   2.29   4.400   13.33   3.33   14.67   2.67   16.00   <		Male	12.57	3.43		13.33	2.67		14.67	2.67		14.50	1.88	
Single   12 00   314   133   333   133   143   1400     Primary education   10.57   3.29   0.077   13.30   2.00   0.108   13.33   3.57   14.00   14.00     Primary education   12.09   3.43   14.00   2.07   14.07   2.67   14.00   14.00     High school   12.09   2.43   14.00   2.67   0.006   13.31   4.00   15.00   14.00   14.00   14.00   14.00   15.00   14.00	Marital status	Married	12.00	3.29	0.335	13.33	2.67	0.774	14.67	2.67	0.067	14.50	2.00	0.902
No education   1057   3.29   0.077   1200   2.09   0.108   133   3.67   0.129   13.78     Highs school   1.20   3.43   1.33   3.33   1.67   2.67   1.40     Highs reducation   1.20   2.29   3.43   1.40   3.33   1.67   2.67   1.40     Poor   Poor   1.20   2.29   -4.00   1.40   2.67   2.67   2.67   2.67   1.40     Good   1.20   2.29   -4.00   1.40   2.67   2.67   2.67   2.67   1.40     Good   1.20   3.14   0.587   1.40   4.67   2.67   1.40   1.40     Good   Urrently Norking/Retired   1.20   3.14   0.587   1.40   3.20   1.40 </th <th></th> <th>Single</th> <td>12.00</td> <td>3.14</td> <td></td> <td>13.33</td> <td>3.33</td> <td></td> <td>13.33</td> <td>1.33</td> <td></td> <td>14.00</td> <td>3.00</td> <td></td>		Single	12.00	3.14		13.33	3.33		13.33	1.33		14.00	3.00	
Primany oducation   12 00   345   1333   2 67   14 00   14 00   14 00   15 00   14 00	Educational status	No education	10.57	3.29	0.077	12.00	2.00	0.108	13.33	3.67	0.129	13.75	2.75	0.003
High school   12 29   344   14 00   333   14 67   2 67   15 00     Higher education   12 29   3.44   14 00   2.37   3.33   14 67   2 67   15 00     Poor   Moderate   12.57   2.43   < 4.00		Primary education	12.00	3.43		13.33	2.67		14.67	2.67		14.00	2.00	
Higher education   12.00   2.29   4.00   13.33   3.33   4.67   2.67   1.00 <th></th> <th>High school</th> <td>12.29</td> <td>3.43</td> <td></td> <td>14.00</td> <td>3.33</td> <td></td> <td>14.67</td> <td>2.67</td> <td></td> <td>15.00</td> <td>2.50</td> <td></td>		High school	12.29	3.43		14.00	3.33		14.67	2.67		15.00	2.50	
Poor   Honderate   10.29   2.29   4.0001   12.67   4.000   13.33   4.00   0.016   14.00     Good   12.57   3.43   14.00   4.56   4.83   14.67   2.67   0.995   14.50     Good   12.57   3.14   0.587   14.00   4.50   0.329   14.67   2.67   0.995   14.50     Currently Working/Relined   12.00   3.14   0.999   13.33   3.33   14.67   2.67   0.995   14.50     Beast   12.00   3.14   0.999   13.33   3.00   0.749   14.67   2.67   0.536   14.00     Beast   12.00   3.49   13.33   3.67   4.67   4.00   14.67   3.67   4.00   14.67   3.67   14.00   14.00   14.67   4.00   14.67   4.00   14.00   14.67   4.00   14.60   14.67   4.00   14.67   4.00   14.60   14.67   4.00   14.00   14.00   14		Higher education	12.00	2.29		13.33	3.33		14.67	2.67		15.00	2.50	
Moderate   12.57   2.43   14.00   2.67   14.50   14.50     Good   Good   12.57   3.40   6.89   14.67   3.00   16.50   16.50     Currently Working   12.57   3.40   0.587   14.60   4.80   0.329   14.67   2.67   0.995   14.50     Lung   12.00   3.44   0.587   14.00   0.749   13.33   2.67   0.536   14.00     Breast   12.00   4.30   4.30   0.749   13.33   2.67   0.536   14.00     Stomach   12.00   4.30   13.33   3.67   14.67   3.33   14.00     Colorectal   12.00   4.57   14.00   2.67   4.00   14.67   4.00   14.67   4.00   14.50     Gynecological origin   12.57   2.71   14.00   3.67   4.00   0.749   14.67   4.00   14.67   4.00   14.67   4.00   14.67   4.00   14.67   4.00 <t< th=""><th>Perceived economic status</th><th>Poor</th><td>10.29</td><td>2.29</td><td>&lt;0.001</td><td>12.67</td><td>2.67</td><td>9000</td><td>13.33</td><td>4.00</td><td>0.016</td><td>14.00</td><td>3.00</td><td>&lt;0.001</td></t<>	Perceived economic status	Poor	10.29	2.29	<0.001	12.67	2.67	9000	13.33	4.00	0.016	14.00	3.00	<0.001
Good   12.57   3.00   14.67   4.83   14.67   3.00   16.50     Currently Morking   12.29   3.14   0.587   14.00   4.80   0.329   14.67   2.67   0.995   14.50     Currently Nortworking/Retired   12.00   3.14   0.909   13.33   3.33   14.67   2.67   0.995   14.50     Lung   12.00   3.14   0.909   13.33   3.67   0.749   13.33   2.67   0.536   14.00     Stomach   12.00   2.57   3.86   4.00   0.749   13.33   2.67   0.536   14.00     Colorectal   12.00   2.57   4.57   14.00   2.67   4.00   14.67   4.00   14.67   4.00   14.67   4.00   14.67   4.00   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14.50   14		Moderate	12.57	2.43		14.00	2.67		14.67	2.67		14.50	2.00	
Currently Working   12.9   3.14   0.587   14.00   4.50   0.450   14.67   2.67   0.995   14.50     Lumently Morking/Redired   12.00   3.43   13.33   3.33   14.67   2.67   0.995   14.50     Breast   12.00   3.14   0.909   13.33   3.67   14.67   2.67   0.536   14.00     Breast   12.00   2.40   13.33   3.67   14.67   3.67   14.00     Colorectal   12.00   2.57   13.33   3.67   14.67   4.00   14.00     Hematological origin   12.86   4.43   13.00   3.67   14.67   4.00   14.00     Thyroid   12.00   4.29   13.33   3.67   4.00   14.00   14.00     Other GIS organs   11.43   5.14   12.67   4.00   13.33   4.67   4.00   14.50     Other GIS organs   11.43   5.14   12.67   4.00   13.33   4.67   4.00   14.50 </th <th></th> <th>Good</th> <td>12.57</td> <td>3.00</td> <td></td> <td>14.67</td> <td>4.83</td> <td></td> <td>14.67</td> <td>3.00</td> <td></td> <td>16.50</td> <td>3.00</td> <td></td>		Good	12.57	3.00		14.67	4.83		14.67	3.00		16.50	3.00	
Currently Not Working/Retired   12.00   34.3   13.3   3.33   1467   267   1450     Lung   Lung   12.00   3.14   0.909   13.33   4.00   0.749   13.33   2.67   0.636   14.00     Bernarch   12.00   4.00   4.00   13.33   3.67   14.67   3.33   14.00     Colorectal   12.00   2.57   13.33   3.67   14.67   4.00   14.50     Hematological origin   12.87   4.57   14.00   2.67   14.67   4.00   14.50     Gynecological origin   12.80   4.43   3.00   2.67   4.00   14.67   4.00   14.00     Gynecological origin   12.80   4.25   12.67   2.73   14.67   4.00   14.00 <td< th=""><th>Employment status</th><th>Currently Working</th><th>12.29</th><th>3.14</th><th>0.587</th><th>14.00</th><th>4.50</th><th>0.329</th><th>14.67</th><th>2.67</th><th>0.995</th><th>14.25</th><th>2.50</th><th>0.931</th></td<>	Employment status	Currently Working	12.29	3.14	0.587	14.00	4.50	0.329	14.67	2.67	0.995	14.25	2.50	0.931
Lung   Lung   12.00   3.14   0.909   13.33   4.00   0.749   13.33   2.67   0.536   14.00     Stomestal   12.57   3.86   14.00   2.67   14.67   3.33   14.00     Stomestal   12.50   4.70   13.33   3.00   14.67   4.00   14.70     Colorectal   12.00   4.75   13.33   3.00   14.67   4.00   14.00     Colorectal   12.00   4.37   13.00   2.67   4.67   4.00   14.00     Colorectal   12.50   4.35   14.00   2.67   4.00   14.00   14.00     Colorectol   10.00   0.00   10.00   13.33   3.67   4.00   14.00   14.00     Colorectol   11.43   5.14   12.67   4.00   14.67   4.00   14.50     Other GIS organs   11.43   5.14   13.33   3.67   4.00   14.67   4.00   14.50     Other GIS organs   11.43		Currently Not Working/Retired		3.43		13.33	3.33		14.67	2.67		14.50	2.00	
Breast   12.57   3.86   14.00   2.67   14.67   3.67   14.75     Colorecal   12.00   4.00   13.33   3.67   14.67   3.33   14.00     Colorecal   12.00   2.57   13.33   3.67   14.67   4.00   14.00     Hematological origin   12.86   4.43   13.00   3.67   13.33   4.67   4.00   14.00     Thyroid   12.00   0.00   13.33   0.00   13.33   4.67   14.00   14.00     Thyroid   12.00   4.29   12.67   4.00   14.67   4.00   14.50     Other GIS organs   11.43   5.14   12.67   4.00   14.67   4.00   15.00     Other GIS organs   11.43   5.14   12.67   4.00   14.67   4.00   15.00     Other GIS organs   11.43   3.14   2.67   4.00   14.67   4.00   14.50     No   12.00   3.43   0.384   13.33   3.33 <th>Type of cancer</th> <th>Lung</th> <td>12.00</td> <td>3.14</td> <td>606.0</td> <td>13.33</td> <td>4.00</td> <td>0.749</td> <td>13.33</td> <td>2.67</td> <td>0.536</td> <td>14.00</td> <td>1.50</td> <td>0.928</td>	Type of cancer	Lung	12.00	3.14	606.0	13.33	4.00	0.749	13.33	2.67	0.536	14.00	1.50	0.928
Stomach   12.00   4.00   13.33   3.67   14.67   3.33   14.00     Colorectal   12.00   2.57   13.33   3.67   14.67   4.00   14.50     Colorectal   12.00   2.57   13.33   3.00   14.67   4.00   14.50     Gynecological origin   12.87   4.43   13.33   0.00   13.33   4.07   14.67   4.00   14.00     Thyroid   12.00   4.29   12.67   2.33   0.00   13.33   6.00   14.67   4.00   15.00     Other organs   11.43   5.14   12.67   4.00   14.67   4.00   14.5		Breast	12.57	3.86		14.00	2.67		14.67	3.67		14.75	2.88	
Colorectal   12.00		Stomach	12.00	4.00		13.33	3.67		14.67	3.33		14.00	1.75	
Hematological origin   12.57   4.57   14.00   2.67   14.67   4.00   14.00     Gynecological origin   12.86   4.43   13.00   3.67   13.33   4.67   14.00   15.00     Gynecological origin   12.86   4.43   13.00   3.67   13.33   4.67   1.00   15.00     Bladder   12.00   4.29   12.67   2.33   14.67   1.00   15.00     Other organs   11.43   5.14   12.67   4.00   14.67   2.67   4.00   15.00     No   Other organs   12.00   2.86 <b>0.027</b> 13.33   3.67   14.67   2.67   4.00   14.75     No   13.14   3.14   14.00   3.33   0.00   14.67   2.67   4.00   14.50     No   10.86   5.43   0.38   13.33   2.67   4.07   14.67   14.60     Children   11.43   3.43   0.00   0.00   14.00   14.67   14.67 </th <th></th> <th>Colorectal</th> <td>12.00</td> <td>2.57</td> <td></td> <td>13.33</td> <td>3.00</td> <td></td> <td>14.67</td> <td>4.00</td> <td></td> <td>14.50</td> <td>2.50</td> <td></td>		Colorectal	12.00	2.57		13.33	3.00		14.67	4.00		14.50	2.50	
Gynecological origin   12.86   443   13.00   3.67   13.33   4.67   14.50   14.50     Thyroid   12.00   0.00   13.33   0.00   13.33   0.00   13.39   0.00   15.00     Bladder   12.00   4.29   12.67   2.33   14.67   1.33   14.67   14.67   14.00   15.00     Other GIS organs   11.43   5.14   13.33   3.67   14.67   2.67   4.00   15.00     Ves   12.57   2.71   13.33   2.83 <b>0.020</b> 14.67   2.67   4.67   14.50     No   19.84   3.43   0.384   13.33   2.67   0.01   4.67   14.50     Partner   10.86   5.43   0.38   12.67   2.67   0.01   14.50     Other   11.43   3.43   0.38   12.67   2.67   0.01   14.67   14.67   14.67   14.67   14.67   14.60   13.33   13.33   13.33   13.33<		Hematological origin	12.57	4.57		14.00	2.67		14.67	4.00		14.00	2.50	
Thyroid   12.00   0.00   13.33   0.00   13.33   0.00   15.00     Bladder   12.00   4.29   12.67   2.33   14.67   1.33   14.57   1.33   14.57   1.33   14.57   1.33   14.57   1.33   14.57   1.33   14.67   4.00   15.00   15.00   14.57   1.33   2.83   0.020   14.67   2.67   4.08   14.50		Gynecological origin	12.86	4.43		13.00	3.67		13.33	4.67		14.50	2.00	
Bladder   12.00   4.29   12.67   2.33   14.67   1.33   14.57     Other GIS organs   11.43   5.14   12.67   4.00   14.67   4.00   15.00     Other organs   12.77   2.71   13.33   3.67   14.67   2.67   4.00   15.00     Yes   12.00   2.86 <b>0.027</b> 13.33   2.83 <b>0.020</b> 14.67   4.67   14.80   14.50     No   12.00   3.43   0.384   13.33   2.67   4.67   4.67   4.00   14.50     Partner   12.57   4.00 <b>0.002</b> 14.00   3.33   0.018   14.67   2.67 <b>-0.001</b> 14.50     Other   11.43   3.43   12.67   2.67   0.018   14.50   14.50     Other   11.257   2.86   0.270   14.00   3.33   2.67   0.734   14.66   2.67   0.030   14.50     Post   12.00   3.43   0.616   13.33		Thyroid	12.00	0.00		13.33	0.00		13.33	0.00		15.00	0.00	
Other GIS organs   11.43   5.14   12.67   4.00   14,67   4.00   15.00     Other organs   12.57   2.71   13.33   3.67   4.00   14,67   2.67   4.00   15.00     Yes   12.00   2.86   0.027   13.33   2.83   0.020   14.67   1.33   0.418   14.50     No   13.14   3.14   3.14   13.33   2.83   0.020   14.67   4.67   14.50   14.50     No   10.86   5.43   0.384   13.33   2.67   0.18   14.67   2.67   <0.01		Bladder	12.00	4.29		12.67	2.33		14.67	1.33		14.25	1.25	
Other organs   12.57   2.71   13.33   3.67   14.67   2.67   14.75   14.75     Yes   12.00   2.86 <b>0.027</b> 13.33   2.83 <b>0.020</b> 14.67   1.33   0.418   14.50     No   13.14   3.14   0.384   13.33   2.87   0.60   14.67   2.67   -6.00   14.50     No   10.86   5.43   0.384   13.33   2.67   0.67   4.67   2.67   -6.00   14.50     Partner   10.86   5.43   0.384   13.33   2.67   0.67   4.67   2.67   -6.00   14.50     Partner   11.43   3.43   0.002   14.00   3.33   0.018   14.67   2.67   0.097   14.50     Other   12.00   3.14   13.67   3.33   2.67   0.734   14.66   4.00   0.764   14.50     No   12.00   3.43   0.616   13.33   2.67   0.931   14.67   2.67 </th <th></th> <th>Other GIS organs</th> <td>11.43</td> <td>5.14</td> <td></td> <td>12.67</td> <td>4.00</td> <td></td> <td>14.67</td> <td>4.00</td> <td></td> <td>15.00</td> <td>3.50</td> <td></td>		Other GIS organs	11.43	5.14		12.67	4.00		14.67	4.00		15.00	3.50	
Yes   12.00   2.86   0.027   13.33   2.83   0.020   14.67   1.33   0.418   14.50     No   13.14   3.14   3.14   14.00   3.33   0.760   14.67   4.67   4.67   14.50     No   10.86   5.43   0.002   14.00   3.33   0.760   14.67   2.67   <0.001   14.50     Partner   10.86   5.43   0.002   14.00   3.33   0.018   14.67   2.67   <0.001   14.50     Children   11.43   3.43   12.67   2.67   0.018   14.67   2.67   0.097   14.00     Other   12.00   3.14   13.67   3.33   0.734   14.66   4.00   0.764   14.50     No   12.00   3.43   13.33   2.67   0.734   14.66   2.67   0.030   14.50     No   12.00   3.43   0.616   13.33   2.67   0.931   14.67   2.67   0.030		Other organs	12.57	2.71		13.33	3.67		14.67	2.67		14.75	2.38	
No   13.14   3.14   14.00   3.33   14.67   4.67   4.67   14.50   14.50     Yes   12.00   3.43   0.384   13.33   3.33   0.760   14.67   2.67 <b>6.001</b> 14.50     No   10.86   5.43   13.33   2.67   0.018   14.67   2.67   0.097   14.50     Partner   12.57   4.00 <b>0.002</b> 14.00   3.33 <b>0.018</b> 14.67   2.67   0.097   14.50     Children   11.43   3.43   12.67   2.67   0.734   14.67   1.33   14.00     Other   12.00   3.43   13.33   2.67   0.734   14.66   2.67   0.030   14.50     No   12.00   3.43   13.33   2.67   0.931   14.67   2.67   0.030   14.50     Yes   12.00   3.43   0.616   13.33   3.33   0.402   14.67   2.67   0.030   14.00     Yes	Have a comorbidity	Yes	12.00	2.86	0.027	13.33	2.83	0.020	14.67	1.33	0.418	14.50	1.50	0.384
Yes   12.00   3.43   0.384   13.33   3.33   0.760   14.67   2.67   <0.001		No	13.14	3.14		14.00	3.33		14.67	4.67		14.50	2.75	
No   10.86   5.43   13.33   2.67   10.67   4.67   12.50   12.50     Partner   12.57   4.00 <b>0.002</b> 14.00   3.33 <b>0.018</b> 14.67   2.67   0.097   14.50     Children   11.43   3.43   12.67   2.67   14.67   1.33   14.00     Other   12.00   3.14   13.67   3.33   2.67   14.67   4.03   0.764   14.50     No   12.00   3.43   0.616   13.33   2.67   0.931   14.66   2.67   0.030   14.50     No   12.00   3.57   13.33   2.67   0.931   14.67   2.67   0.030   14.00     Yes   12.00   3.43   0.680   13.33   3.33   0.402   14.67   2.67   0.030   14.00     No   12.57   2.86   13.33   3.33   0.402   14.67   2.67   0.367   14.00     No   12.57   2.86	Have a caregiver	Yes	12.00	3.43	0.384	13.33	3.33	0.760	14.67	2.67	<0.001	14.50	2.00	0.082
Partner   12.57   4.00 <b>0.002</b> 14.00   3.33 <b>0.018</b> 14.67   2.67   0.097   14.50     Children   11.43   3.43   12.67   2.67   2.67   14.67   1.33   14.00     -19   Yes   12.00   3.14   13.67   3.33   2.67   0.734   14.66   4.00   0.764   14.50     No   Yes   12.00   3.43   13.33   2.67   0.931   14.66   2.67   0.030   14.50     Poss   No   12.00   3.59   0.616   13.33   2.67   0.931   14.67   2.67   0.030   14.50     Poss   12.00   3.43   0.680   13.33   3.33   0.402   14.67   2.67   0.030   14.00     Poss   12.00   3.43   0.680   13.33   3.33   0.402   14.67   2.67   0.030   14.00     Poss   12.57   2.86   13.33   3.33   0.402   14.67		No	10.86	5.43		13.33	2.67		10.67	4.67		12.50	3.75	
Children   11.43   3.43   12.67   2.67   14.67   1.33   1.33   14.00     -19 Ves   12.00   3.14   13.67   3.33   2.67   0.734   14.66   4.00   0.764   14.50     No   12.00   3.43   0.616   13.33   2.67   0.931   14.66   2.67   0.030   14.50     P No   12.00   3.59   0.616   13.33   2.67   0.931   14.67   2.67   0.030   14.50     P No   12.00   3.43   0.680   13.33   3.33   0.402   14.67   2.67   0.030   14.00     No   12.57   2.86   13.33   3.33   0.402   14.67   2.67   0.367   14.00	Who is the caregiver	Partner	12.57	4.00	0.002	14.00	3.33	0.018	14.67	2.67	0.097	14.50	2.50	0.044
Other   12.00   3.14   13.67   3.33   13.33   4.33   15.00     -19   Yes   12.57   2.86   0.270   13.33   2.67   0.734   14.66   4.00   0.764   14.50     No   12.00   3.43   0.616   13.33   2.67   0.931   14.67   2.67   0.030   14.50     9   No   12.00   3.57   13.33   3.33   0.402   14.67   2.67   0.030   14.00     Yes   12.00   3.43   0.680   13.33   3.33   0.402   14.67   2.67   0.367   14.50     No   12.57   2.86   13.33   3.33   3.33   0.402   14.67   2.67   0.367   14.00		Children	11.43	3.43		12.67	2.67		14.67	1.33		14.00	2.00	
-I9 Ves   Yes   12.57   2.86   0.270   13.33   2.67   0.734   14.66   4.00   0.764   14.50     No   12.00   3.43   13.33   2.67   0.931   14.66   2.67   0.030   14.25     9 No   No   12.00   3.57   13.33   3.33   0.402   14.67   2.67   0.030   14.00     No   12.57   2.86   13.33   3.33   0.402   14.67   2.67   0.367   14.50		Other	12.00	3.14		13.67	3.33		13.33	4.33		15.00	3.63	
No   12.00   3.43   13.33   3.33   14.66   2.67   0.030   14.25     Yes   12.00   3.29   0.616   13.33   2.67   0.931   14.67   2.67   0.030   14.50     No   Yes   12.00   3.43   0.680   13.33   3.33   0.402   14.67   2.67   0.367   14.50     No   12.57   2.86   13.33   3.33   13.33   4.00   14.00	Diagnosed with COVID-19	Yes	12.57	2.86	0.270	13.33	2.67	0.734	14.66	4.00	0.764	14.50	2.50	0.907
Yes   12.00   3.29   0.616   13.33   2.67   0.931   14.67   2.67   0.030   14.50     9   No   12.00   3.43   0.680   13.33   3.33   0.402   14.67   2.67   0.367   14.00     No   12.57   2.86   13.33   3.33   0.402   14.67   2.67   0.367   14.50		No	12.00	3.43		13.33	3.33		14.66	2.67		14.25	2.00	
9   No   12.00   3.57   13.33   3.33   14.67   2.67   14.00     Yes   12.00   3.43   0.680   13.33   3.33   0.402   14.67   2.67   0.367   14.50     No   12.57   2.86   13.33   3.33   13.33   4.00   14.00	Have an acquaintance	Yes	12.00	3.29	0.616	13.33	2.67	0.931	14.67	2.67	0.030	14.50	2.00	0.231
Yes 12.00 3.43 0.680 13.33 3.33 0.402 14.67 2.67 0.367 14.50   No 12.57 2.86 13.33 3.33 13.33 4.00 14.00	died due to COVID-19	No	12.00	3.57		13.33	3.33		14.67	2.67		14.00	2.50	
No 12.57 2.86 13.33 3.33 13.33 4.00 14.00	Had at least two shots	Yes	12.00	3.43	0.680	13.33	3.33	0.402	14.67	2.67	0.367	14.50	2.00	0.220
	COVID-19 vaccine	No	12.57	2.86		13.33	3.33		13.33	4.00		14.00	3.00	

\*IQR: interquartile range

#### **DISCUSSION**

This study showed that patients receiving chemotherapy had higher levels of COVID-19 phobia and lower quality of life in some sub-scales. In our assessed population, those with underlying illnesses had significantly higher scores in somatic and economic subscales of the COVID-19 phobia scale, in addition to lower psychological health sub-scale scores. A research conducted by Koçak et al14 showed that anxiety and stress levels were significantly high in patients who have underlying diseases and witness family/friends being infected with or dying due to COVID-19. A survey carried out in Wuhan by Qian et al<sup>15</sup> showed that more than half of the participants had a significant level of anxiety; almost all of them stated that their life was affected by COVID-19, and they needed mental support. Also, in a cohort study that assessed COVID-19 hospitalization and death-related predictors within the first 9515 cases in Denmark, risk factors such as the number of comorbidities had a significant impact on hospitalization and death of COVID-19 positive patients<sup>16</sup>.

Cancer patients' quality of life was getting affected and was inevitable while continuing the course of treatment under difficult conditions<sup>17</sup>. This was observed in our findings; cancer patients with lower economic status had significantly lower quality of life in all aspects. Ciążynska et al <sup>18</sup> had found resembling results to those findings. They showed cancer patients living alone had lower quality of life which indicates the importance of caregivers and their impact on patients' well-being and making progress on their treatment. Also, they showed they had lower quality of life during the pandemic, in their financial status, and cognitive and social functioning, compared to the data gathered under normal conditions.

In our study age was an important factor that affects the quality of a cancer patient's life. Older patients dealing with their illness during the burdensome conditions of the pandemic had lower quality of life scores when compared to much younger patients. With increasing age, people tend to become more dependent on surrounding family, acquaintances, and facilities. A cross-sectional Danish study conducted by Jeppesen et al<sup>19</sup> found age to be an important predictor of mortality due to COVID-19 and supposed that as age increases, quality of life decreases. Also, in this study resembling our findings, it was observed that people who concern about being infected with COVID-19 had lower quality of life scores.

Overall, we can state that patients at high risk such as cancer patients have been critically affected by the pandemic. They experienced a high level of phobia and in return, their well-being worsened during this time. We have found that as COVID-19 phobia levels increases, the patient's quality of life declines. This similar inverse correlation was interpreted in Dönmez et al<sup>20</sup> research carried out on cancer patients during the pandemic.

Limitations of this study include the fact that it's cross-sectional, hence it only interprets the present perception of cancer patients receiving chemotherapy at a single institute regarding their situation during the COVID-19 pandemic. In future studies, instead of convenient sampling, a random sampling method can be applied to a larger sample size of patients receiving chemotherapy across several institutes in Istanbul. Confounding factors that may affect the quality of life independent of COVID-19, for example, stage of cancer, number of chemotherapy sessions etc. can be further studied and asked in detail to establish stronger relations in our results.

Regarding our study's strength points we had rather included a wide range of age and cancer types instead of focusing on one type. At the time we carried out our research, the impact of COVID-19 was mitigating. Hence, it can be useful to compare with research conducted at the beginning of the pandemic and weigh up the impact of the change on people's perceptions and responses.

#### **CONCLUSIONS**

COVID-19 phobia and quality of life levels were observed inverse relationship in patients receiving chemotherapy in a state hospital. Patients who have an acquaintance who died due to COVID-19 tend to show higher levels of COVID-19 phobia. In addition, lower scores on physical and psychological subscales of quality of life were observed in patients who have comorbidities whilst they had higher levels of COVID-19 phobia. Lastly, those who have better economic status had an improved quality of life within all its subscales.

### FINANCIAL SUPPORT:

None.

#### ETHICS APPROVAL AND CONSENT TO PARTICIPATE:

Ethics approval was obtained from the Local Ethics Committee. Oral and written consent was obtained from the participants.

### CONSENT FOR PUBLICATION:

All authors give their consent for publication.

#### AVAILABILITY OF DATA AND MATERIAL:

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.



# World Cancer Research Journal

#### **CONFLICT OF INTERESTS:**

The authors declare that they have no conflict of interest.

#### **FUNDING:**

No funding is declared for this article.

#### **AUTHORS CONTRIBUTIONS:**

Conception and design of the study by Seyhan Hıdıroğlu, Beyza Nur Ataoğlu, Ege Pastırmacıoğlu, Gizem Çakır, Söğüt Yorgancı, Alisar Ghachem; analysis and interpretation of data by Beyza Nur Ataoğlu; drafting the article or making critical revisions related to relevant intellectual content of the manuscript by all authors; validation and final approval of the version of the article by Seyhan Hıdıroğlu.

#### **ORCID ID**

Seyhan Hıdıroğlu: 0000-0001-8656-4613 Beyza Nur Ataoğlu: 0000-0001-5202-0458 Ege Pastırmacıoğlu: 0000-0002-5929-2242 Gizem Çakır: 0000-0001-9659-0508 Söğüt Yorgancı: 0000-0003-0935-1803 Alisar Ghachem: 0000-0002-0231-4797

#### **REFERENCES**

- Cucinotta D, Vanelli M. Who declares COVID-19 a pandemic. Acta bio-medical: Atenei Parmen-sis 2020; 91: 157-160.
- Niuz Morshed Khan M, Sharif Sarker M. Coronavirus 2019 (Covid-19), A Life Threating Disease All Over The World. WCRJ 2020; 7: e1586.
- Chen G, Wu Q, Jiang H, Zhang H, Peng J, Hu J, Chen M, Zhong Y, Xie C. Fear of disease progression and psychological stress in cancer patients under the outbreak of COVID-19. Psycho Oncology 2020; 29: 1395-1398.
- 4. Akat M, Karataş K. Psychological Effects of COVID-19 Pandemic on Society and Its Reflections on Education. J Turkish Studies 2020; 15: 1-13.
- 5. Kurt S, Karaaziz M. Covid-19 Pandemisinin Psikososyal Alandaki Etkileri. J Faculty Arch 2021; 3: 81-91.
- https://corona.hacettepe.edu.tr/wp-content/up-loads/2020/06/Covid-19\_psikolojik\_sonuclari\_basa\_cikma\_yontemleri.pdf (accessed July 12, 2022)
- https://www.nhs.uk/mental-health/conditions/phobias/overview/ (accessed April 24, 2022)
- 8. Arora A, Jha AK, Alat P, Das SS. Understanding coronaphobia. Asian J Psychiatry 2020; 54: 102384.

- 9. https://www.who.int/publications/i/item/WHO-HIS-HSI-Rev.2012.03(accessed September 24, 2021)
- https://hsgm.saglik.gov.tr/tr/kanser-tedavisi (accessed March 25, 2022)
- Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009; 7: 102.
- 12. Arpaci I, Karataş K, Baloğlu M. The development and initial tests for the psychometric properties of the COVID-19 Phobia Scale (C19P-S). Pers Individ Diff 2020; 164: 110108.
- 13. Eser E, Fidaner H, Fidaner C, Eser S, Elbi H, Göker E. Psychometric properties of the WHOQOL-100 and WHOQOL-BREF. J Psychiatry Psychol Psychopharmacol 1999; 7: 23-40.
- 14. Koçak O, Koçak ÖE, Younis MZ. The Psychological Consequences of COVID-19 Fear and the Moderator Effects of Individuals' Underlying Illness and Witnessing Infected Friends and Family. Int J Env Res Public Health 2021; 18: 1836.
- 15. Qian Y, Wu K, Xu H, Bao D, Ran F, Wei W, Cheng T, Huang D, Lin X, Bruera E, Hu D, Wu Y. A survey on physical and mental distress among cancer patients during the COVID-19 Epidemic in Wuhan, China. J Palliat Med 2020; 23: 888-889.
- 16. Reilev M, Kristensen KB, Pottegaard A, Lund LC, Hallas J, Ernst MT, Christiansen CF, Sørensen HT, Johansen NB, Brun NC, Voldstedlund M, Støvring H, Thomsen MK, Christensen S, Gubbels S, Krause TG, Mølbark K, Thomsen RW. Characteristics and predictors of hospitalization and death in the first 9519 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. medRxiv 2020.
- Weaver MS, Howard SC, Lam CG. Defining and Distinguishing Treatment Abandonment in Patients With Cancer. J Pediatric Hematol Oncol 2015; 37: 252-256.
- Ciążyńska, M, Pabianek, M, Szczepaniak, K, Ułańska, M, Skibińska, M, Owczarek, W, Narbutt, J, Lesiak, A. Quality of life of cancer patients during coronavirus disease (COVID-19) pandemic. Psychooncology 2020; 29: 1377-1379.
- Jeppesen SS, Bentsen KK, Jørgensen TL, Holm, HS, Holst-Christensen L, Tarpgaard LS, Dahlrot Lise Eckhoff RK. Quality of life in patients with cancer during the COVID-19 pandemic – a Danish cross-sectional study (COPICADS). Acta Oncologica 2021; 60: 4-12.
- Dönmez E, Temiz G, Dülger Z, Bayram Z, Berker Döğer BN, Acar O, Demirci NS. The effects of COVID-19 phobia on quality of life: a cross-sectional study of cancer patients. WCRJ 2021; 8: e1965.